Preimplantation genetic screening 2.0: the theory

Area of Science:

• Reproductive medicine
• Genetics
• Embryology

Background:

• A new generation of preimplantation genetic screening (PGS) has emerged.
• PGS 2.0 aims to improve in vitro fertilization (IVF) success rates.
• Current evidence from randomized controlled trials (RCTs) is lacking to confirm its benefits.

Purpose of the Study:

• To provide an overview of Preimplantation Genetic Screening (PGS) 2.0.
• To discuss indications, optimal biopsy timing, and molecular techniques.
• To evaluate the potential of PGS 2.0 in improving IVF outcomes.

Main Methods:

• Review of current PGS 2.0 strategies.
• Discussion of biopsy techniques, favoring trophectoderm biopsy over cleavage stage.
• Analysis of molecular methods for assessing aneuploidy across all 24 chromosomes.

Main Results:

• PGS 2.0 has various potential indications.
• Trophectoderm biopsy is preferred over cleavage stage biopsy.
• Improved vitrification methods facilitate frozen embryo transfer, often replacing fresh transfers.
• Multiple methods exist for analyzing aneuploidy of all 24 chromosomes.

Conclusions:

• The success of PGS 2.0 hinges on effective biopsy strategies and comprehensive chromosomal analysis.
• Defining and comparing IVF success metrics across studies remains challenging.
• The optimal application and patient groups for PGS 2.0 are yet to be determined.